

CARBOPLATIN

INDICATION (ICD10) C50, C54, C56

1. Triple negative or BRCA mutated metastatic breast cancer (case based discussion).
2. Frontline chemotherapy in ovarian carcinoma.
3. Relapsed (non-refractory) ovarian carcinoma who have not relapsed during 1st line platinum based chemotherapy.
4. Endometrial carcinoma.
5. Serous papillary uterine cancer
PS 0, 1, 2

REGIMEN

Day 1 CARBOPLATIN AUC 5 in 500ml glucose 5% IV infusion over 30 minutes.

Dose calculated by EDTA GFR or calculated $(CrCl + 25) \times AUC$.

Non- breast indications - maximum dose when using CrCl $(125+25 \times AUC)$ mg

Breast cancer - maximum dose when using CrCl is 700mg

CYCLE FREQUENCY AND NUMBER OF CYCLES

Non-ovarian - every 21 days for 6 cycles

Ovarian - every 21 days for 6 cycles (an additional 2 cycles may be given following debulking surgery ie up to 8 cycles)

ANTI-EMETICS

Moderate risk day 1

CONCURRENT MEDICATION REQUIRED

Carboplatin	Anaphylaxis treatment should be prescribed if the patient has had an anaphylactic episode previously. Dexamethasone 20mg IV bolus Chlorphenamine 10mg IV bolus H ₂ antagonist Carboplatin should be given at a slower rate e.g. 2-4 hours.
-------------	---

EXTRAVASATION AND TYPE OF LINE / FILTERS

Carboplatin - irritant

Filter not required

Peripheral or central line

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils $\times 10^9/L \geq 1.5$

Platelets $\times 10^9/L \geq 100$

GFR assessed using EDTA result or calculated creatinine clearance at the Consultant's discretion.

Patients with hydronephrosis or serum creatinine ≥ 100 micromol/L need a serum creatinine checked every cycle.

CA125 baseline and day 1 every cycle for gynae patients

Baseline weight and every cycle

MAIN TOXICITIES AND ADVERSE REACTIONS

Carboplatin	Ototoxicity – monitor Neurotoxicity - monitor
-------------	--

DOSE MODIFICATIONS

Carboplatin

GFR/ calculated CrCl ≤ 20 ml/min or ≤ 30 ml/min with pre-existing severe renal impairment	contraindicated
---	-----------------

REFERENCES

1. Tutt A, et al: The TNT trial. 2014 San Antonio Breast Cancer Symposium. Abstract S3-01. Presented December 11, 2014.
2. The Lancet Oncology Volume 15, No. 7, p747–756, November 2014
3. Prof Gunter von Minckwitz, MD, Prof Andreas Schneeweiss, MD, Prof Sibylle Loibl, MD, Christoph Salat, MD, Prof Carsten Denkert, MD, Prof Mahdi Rezai, MD, Prof Jens U Blohmer, MD, Prof Christian Jackisch, MD, Stefan Paepke, MD, Prof Bernd Gerber, MD, Dirk M Zahm, MD, Sherko Kümmel, MD, Holger Eidtmann, MD, Peter Klare, MD, Prof Jens Huober, MD, Prof Serban Costa, MD, Prof Hans Tesch, MD, Claus Hanusch, MD, Prof Jörn Hilfrich, MD, Fariba Khandan, MD, Prof Peter A Fasching, MD, Bruno V Sinn, MD, Knut Engels, MD, Keyur Mehta, MBA, Valentina Nekljudova, PhD, Prof Michael Untch, MD Published Online: 30 April 2014
4. Taylor, AE, E Wiltshaw, et al, Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. *J Clin Oncol*, 1994 12(10): p2066-70.
5. Colombo, N., D. Guthrie, et al., International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst*, 2003. 95(2): p125-32.
6. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. *Lancet*, 1998. 352(9140): p1571-6.
7. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet*, 2002. 360(9332): p505-15.
8. Parmar, M.K., J.A. Ledermann, et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet*, 2003. 361(9375): p2099-106.